Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: a clinical outcome study

• Published in: Thrombosis and haemostasis Vol. 86; no. 5; p. 1170
• Main Authors: Chong, B H, Gallus, A S, Cade, J F, Magnani, H, Manoharan, A, Oldmeadow, M, Arthur, C, Rickard, K, Gallo, J, Lloyd, J, Seshadri, P, Chesterman, C N
• Format: Journal Article
• Language: English
• Published: Germany 01.11.2001
• Subjects: Aged; Chondroitin Sulfates - administration & dosage; Chondroitin Sulfates - toxicity; Dermatan Sulfate - administration & dosage; Dermatan Sulfate - toxicity; Dextrans - administration & dosage; Dextrans - toxicity; Drug Combinations; Drug Therapy, Combination; Female; Heparin - adverse effects; Heparin - immunology; Heparitin Sulfate - administration & dosage; Heparitin Sulfate - toxicity; Humans; Male; Middle Aged; Prospective Studies; Survival Rate; Therapeutic Equivalency; Thrombocytopenia - chemically induced; Thrombocytopenia - complications; Thrombocytopenia - drug therapy; Thrombosis - complications; Thrombosis - drug therapy; Thrombosis - etiology; Treatment Outcome; Warfarin - administration & dosage

To compare clinical outcomes in a randomised comparison of treatment with danaparoid sodium (a heparinoid), or dextran 70, for heparin-induced thrombocytopaenia (HIT) plus thrombosis. Forty-two patients with recent thrombosis and a clinical diagnosis of probable HIT who presented at ten Australian h...